New Dual-Action antibody takes on advanced cancers

NCT ID NCT06635785

Recruiting now Disease control Sponsor: OncoC4, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: first to find the safest dose, then to see how well it works. About 387 adults with measurable disease will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

AdventHealth Cancer Institute
RECRUITING

Orlando, Florida, 32804, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Henry Ford Health
RECRUITING

Detroit, Michigan, 48202, United States
Highlands Oncology Group
RECRUITING

Springdale, Arkansas, 72762, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
MedStar Georgetown University Hospital
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Memorial Healthcare System
RECRUITING

Hollywood, Florida, 33021, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
Norton Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
Novant Health Cancer Institute
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Ocala Oncology Center PL DBA Florida Cancer Affiliates
RECRUITING

Ocala, Florida, 34474, United States
Prisma Health
RECRUITING

Greenville, South Carolina, 29605, United States
The Ohio State University James Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
The Tisch Cancer Institute, Mount Sinai Medical Center
NOT_YET_RECRUITING

New York, New York, 10029, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35233, United States
University of Florida UF Health Cancer Center
RECRUITING

Gainesville, Florida, 32610, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of North Carolina at Chapel Hill Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Utah Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.